Telbermin

Protein / enzyme therapeutic

DiscontinuedVEGF-ANo recent registered activity
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2015-10), after a negative readout

sNN0029 was Newron Sweden's intracerebroventricular VEGF-A infusion solution for amyotrophic lateral sclerosis. All continuation studies were terminated in October 2015 after an interim review found no favourable benefit-risk ratio, compounded by infusion-system supply problems. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Featured evidence outside this drug's tracked markets:NCT02269436 · Amyotrophic Lateral Sclerosis · Phase 1 · Weak signal

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Other / comorbidity
NCT00351767 · Genentech, Inc.
2006-01 – 2008-01 · Foot Ulcer, Diabetic
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT01384162 · Newron Sweden AB
2009-06 – 2015-10 · Amyotrophic Lateral Sclerosis
What this study did
NCT00800501 · Newron Sweden AB
2008-12 – 2011-06 · Amyotrophic Lateral Sclerosis
What this study did
Phase 1 (3)
Other / comorbidity
NCT01999803 · Newron Sweden AB
2014-09 – 2015-10 · Amyotrophic Lateral Sclerosis
What this study did
NCT02269436 · Newron Sweden AB
2015-01 – 2015-10 · Amyotrophic Lateral Sclerosis
What this study did

Competitive landscape

This mechanism is crowded: 38 other tracked programmes target it, 38 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Telbermin: this drugDiscontinuedProtein / enzyme therapeuticVEGF-AWeak signalNo reviewed efficacy summary
Aflibercept (Eylea)
Approved(overall)
Protein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Reliable signal
NCT00509795: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0)
NCT00637377: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (At week 52): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 95.62% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 96.27% | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 95.56% vs Ranibizumab 0.5mg Q4 94.42%
Aflibercept-Abzv (Enzeevu)
Approved(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary
Aflibercept-Ayyh (Pavblu)
Approved(overall)
Protein / enzyme therapeuticVEGF-AReliable signal
NCT04270747: Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97)
Aflibercept-Boav (Eydenzelt)
Approved(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary
Aflibercept-Jbvf (Yesafili)
Approved(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary
Aflibercept-Mrbb (Ahzantive)
Approved(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary
Aflibercept-Yszy (Opuviz)
Approved(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary
Alymsys (bevacizumab-Maly)
Approved(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary
BAT1706 (Avzivi)
Approved(overall)
Monoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
Bevacizumab
Approved(overall)
Monoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00601900: Progression-free survival: hazard ratio 0.75 (95% CI 0.59 to 0.96; P=.016); median 20.2 months with letrozole plus bevacizumab vs 15.6 months with letrozole alone (CALGB 40503, J Clin Oncol 2016).
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
Bevacizumab-Awwb (MVASI)
Approved(overall)
Monoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
Brolucizumab-Dbll
Approved(overall)
Antibody fragmentVEGF-AReliable signalNo reviewed efficacy summary
Jobevne (bevacizumab-Nwgd)
Approved(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary
Ranibizumab (Lucentis)
Approved(overall)
Antibody fragmentVEGF-APartial signal
NCT00056836: Losing fewer than 15 letters at 12 months: 94.5% (0.3 mg) and 94.6% (0.5 mg) vs 62.2% sham.
Ranibizumab-Eqrn (Cimerli)
Approved(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary
Ranibizumab-Hkdz (Ranluspec)
Approved(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary
Ranibizumab-Leyk (Nufymco)
Approved(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary
Ranibizumab-Nuna (Byooviz)
Approved(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary
Vegzelma (bevacizumab-Adcd)
Approved(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary
Zirabev (bevacizumab-Bvzr)
Approved(overall)
Monoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
BAT5906
Phase 3(overall)
Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary
CKD-701 (Lucenbies)
Phase 3(overall)
Monoclonal antibodyVEGF-AReliable signal
NCT04857177: Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%).
HD204
Phase 3(overall)
Monoclonal antibodyVEGF-AReliable signal
NCT03390686: SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin
HLX04 (Hanbeitai)
Phase 3(overall)
Monoclonal antibodyVEGF-APartial signal
NCT03952403: ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC.
HLX04-O
Phase 3(overall)
Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary
IBI305
Phase 3(overall)
Monoclonal antibodyVEGF-AReliable signal
NCT02954172: Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33.
LY01008
Phase 3(overall)
Monoclonal antibodyVEGF-AReliable signal
NCT03533127: LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated.
Ranibizumab (Ximluci)
Phase 3(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary
Surabgene Lomparvovec
Phase 3(overall)
Gene therapy / editingVEGF-AWeak signal
NCT04832724: Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0
Tarcocimab Tedromer
Phase 3(overall)
Monoclonal antibodyVEGF-AReliable signal
NCT04964089: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76)
NCT04592419: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in BRVO Participants. (Day 1 to Week 24): KSI-301 (Arm A) 14.2 ETDRS Letters (Standard Error 0.81) vs Aflibercept (Arm B) 15.6 ETDRS Letters (Standard Error 0.79)
MW02
Phase 2/3(overall)
Monoclonal antibodyVEGF-APartial signalNo reviewed efficacy summary
Ranibizumab (Rimmyrah)
Phase 1(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary
Aflibercept (Afiveg)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary
Aflibercept (Eyluxvi)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary
Aflibercept (Mynzepli)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary
Aflibercept (Vgenfli)
—(overall)
Protein / enzyme therapeuticVEGF-Anot yet gradedNo reviewed efficacy summary
Ranibizumab (Ranivisio)
—(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary
Ranibizumab (Rexatilux)
—(overall)
Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary

Upcoming events

No upcoming readouts on record for this asset.